Antibody platform

OMR(Order-made Medical Research) succeeded in manufacturing membrane protein antibodies, which was difficult with existing technology, and dramatically expanded the number of target molecules for antibody medicines. By applying and developing this, it has become possible to challenge the field of truly groundbreaking antibody medicines that target intracellular molecules, disease specific immunogenicity changes, which were difficult to target antibodies.

Based on the “National Antibody Cluster” in Hongcheon, Korea, together with Wide River Institute of Immunology, Seoul National University, WHONIZ and OMR are focusing on the industrialization of antibody medicines by producing customized antibodies that target not only viral diseases but also intracellular molecules and specific antigenic changes that were difficult to target with antibodies, and disease treatments so that we can contribute to the ‘Universal Human Health Improvement’.